(Boursier.com) — Theradiag rose 1.8% to 2.08 euros on Wednesday on the Paris stock exchange, while the group announced that Biosynex held to date 25.07% of its capital against 18.8%. Four members of the board have resigned with immediate effect at the end of the AGM of May 5, 2022, while the mandate of Bertrand de Castelnau, CEO of Theradiag, will also expire at the end of this AGM. Their renewal will therefore be submitted to the vote of the shareholders. Following Biosynex’s entry into the capital of Theradiag, the appointments of Messrs. ABENSUR (CEO of Biosynex), LAMY (delegate CEO of Biosynex) and PAPER (delegate CEO of Biosynex) will also be put to the vote.
According to Portzamparc, “Biosynex’s desire to join Theradiag’s Board of Directors indicates that this new shareholder wishes to be involved in its governance, which is positive in our view with regard to Biosynex’s cash reserve (132 ME gross and 97 ME net) as well as its future ambitions for diversification, particularly in the monitoring of biotherapies and Point of Care. We do not rule out a merger and maintain our scenarios” concludes the analyst who is targeting a price of 2.40 euros.
©2022 Boursier.com